Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases.  Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […]